Calendario›MOLN›MP0274
MP0274
First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors
Ensayo de MOLECULAR PARTNERS AG en Neoplasias.
Más ensayos de: Neoplasias.
- Fase
- Fase 1
- Estado
- Completado
- Participantes
- 22
- Centros
- 4
- Fin del objetivo primario
- dic 2021
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, de un solo grupo, abierto. Comenzó en ago 2017.
Qué mide
Incidence and severity of adverse events (from first infusion to end-of-study visit, up to 12 months) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis study is investigating a new experimental therapy, MP0274, a DARPin® drug candidate targeting HER2. Preclinical studies suggest that MP0274 may provide additional benefit for the treatment of HER2-positive cancers. This is the first study of MP0274 in humans and its main purpose is to test its safety and tolerability in patients with HER2-positive cancer. This study will also examine the blood levels of MP0274 at several escalating dose levels and a recommended dose for further development will be determined. The recommended dose will be tested in a second part of the study to confirm safety and to further assess the preliminary biologic and anti-tumor activity
Más ensayos de MOLN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| [212Pb]Pb-MP0712 | Fase 1/2 | Reclutando pacientes | sep 2028 (prevista) |
| MP0533 | Fase 1 | Completado | may 2026 (real) |
| MP0317 | Fase 1 | Interrumpido | ene 2024 (real) |
| MP0310 | Fase 1 | Completado | jun 2022 (real) |
| Ensovibep | Fase 1 | Interrumpido | ene 2022 (real) |
| ensovibep | Fase 2 | Completado | ago 2021 (real) |
Todos los de MOLN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT03084926), actualizada en ene 2022.